Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, Erdemci-Evin S, Mayer B, Hoffmann M, Pöhlmann S, Liu W, Hahn BH, Beil A, Kroschel J, Jahrsdörfer B, Schrezenmeier H, Kirchhoff F, Münch J, Müller JA.
Groß R, et al. Among authors: zanoni m.
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
EBioMedicine. 2022.
PMID: 34929493
Free PMC article.
Clinical Trial.